Premium
Vilazodone no better than placebo or fluoxetine in multisite RCT; open‐label study finds it safe
Publication year - 2020
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30513
Subject(s) - fluoxetine , placebo , major depressive disorder , randomized controlled trial , depression (economics) , open label , medicine , psychiatry , psychology , alternative medicine , serotonin , economics , receptor , cognition , pathology , macroeconomics
Vilazodone was found not effective for pediatric patients with major depressive disorder (MDD) in a recent study comparing it with placebo and fluoxetine. The same improvements in depression were observed in all three arms.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom